Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation

Rafael Holdings, Inc. (RFL) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/19/2021 4 CONKLING WILLIAM (Chief Commercial Officer) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 118,409 options to buy @ $40.85, valued at $4.8M
04/14/2021 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/30/2021 GN Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
03/24/2021 EFFECT Form EFFECT - Notice of Effectiveness:
03/18/2021 3 CONKLING WILLIAM (Chief Commercial Officer) has filed a Form 3 on Rafael Holdings, Inc.
03/17/2021 10-Q Quarterly Report for the period ended January 31, 2021
03/17/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results"
03/11/2021 8-K Quarterly results
03/11/2021 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
02/24/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
02/12/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2021 GN LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil®
02/08/2021 RW Form RW - Registration Withdrawal Request:
01/28/2021 8-K Other Events
01/20/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/19/2021 GN Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
01/19/2021 8-K Quarterly results
01/14/2021 3 JONAS RACHEL (Director) has filed a Form 3 on Rafael Holdings, Inc.
01/13/2021 GN Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
01/07/2021 4 PASCHE BORIS C (Director) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 4,203 shares @ $22.72, valued at $95.5k
01/07/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/07/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/07/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/15/2020 10-Q Quarterly Report for the period ended October 31, 2020
12/15/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports First Quarter Fiscal Year 2021 Results"
12/15/2020 GN UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
12/15/2020 GN Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
12/11/2020 8-K Unregistered Sales of Equity Securities
12/01/2020 GN Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue
11/23/2020 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/10/2020 GN Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
10/29/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2020 Results"
10/29/2020 10-K Annual Report for the period ended July 31, 2020
10/29/2020 GN FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy